Back to Search
Start Over
Survival in patients with spinocerebellar ataxia types 1, 2, 3, and 6 (EUROSCA): a longitudinal cohort study
- Source :
- Lancet Neurology, 17, 4, pp. 327-334, Lancet Neurology, 17, 327-334, The lancet
/ Neurology 17(4), 327-334 (2018). doi:10.1016/S1474-4422(18)30042-5, ResearcherID - Publication Year :
- 2018
-
Abstract
- Summary Background Spinocerebellar ataxias are dominantly inherited progressive ataxia disorders that can lead to premature death. We aimed to study the overall survival of patients with the most common spinocerebellar ataxias (SCA1, SCA2, SCA3, and SCA6) and to identify the strongest contributing predictors that affect survival. Methods In this longitudinal cohort study (EUROSCA), we enrolled men and women, aged 18 years or older, from 17 ataxia referral centres in ten European countries; participants had positive genetic test results for SCA1, SCA2, SCA3, or SCA6 and progressive, otherwise unexplained, ataxias. Survival was defined as the time from enrolment to death for any reason. We used the Cox regression model adjusted for age at baseline to analyse survival. We used prognostic factors with a p value less than 0·05 from a multivariate model to build nomograms and assessed their performance based on discrimination and calibration. The EUROSCA study is registered with ClinicalTrials.gov, number NCT02440763. Findings Between July 1, 2005, and Aug 31, 2006, 525 patients with SCA1 (n=117), SCA2 (n=162), SCA3 (n=139), or SCA6 (n=107) were enrolled and followed up. The 10-year survival rate was 57% (95% CI 47–69) for SCA1, 74% (67–81) for SCA2, 73% (65–82) for SCA3, and 87% (80–94) for SCA6. Factors associated with shorter survival were: dysphagia (hazard ratio 4·52, 95% CI 1·83–11·15) and a higher value for the Scale for the Assessment and Rating of Ataxia (SARA) score (1·26, 1·19–1·33) for patients with SCA1; older age at inclusion (1·04, 1·01–1·08), longer CAG repeat length (1·16, 1·03–1·31), and higher SARA score (1·15, 1·10–1·20) for patients with SCA2; older age at inclusion (1·44, 1·20–1·74), dystonia (2·65, 1·21–5·53), higher SARA score (1·26, 1·17–1·35), and negative interaction between CAG and age at inclusion (0·994, 0·991–0·997) for patients with SCA3; and higher SARA score (1·17, 1·08–1·27) for patients with SCA6. The nomogram-predicted probability of 10-year survival showed good discrimination ( c index 0·905 [SD 0·027] for SCA1, 0·822 [0·032] for SCA2, 0·891 [0·021] for SCA3, and 0·825 [0·054] for SCA6). Interpretation Our study provides quantitative data on the survival of patients with the most common spinocerebellar ataxias, based on a long follow-up period. These results have implications for the design of future interventional studies of spinocerebellar ataxias; for example, the prognostic survival nomogram could be useful for selection and stratification of patients. Our findings need validation in an external population before they can be used to counsel patients and their families. Funding European Union 6th Framework programme, German Ministry of Education and Research, Polish Ministry of Scientific Research and Information Technology, European Union 7th Framework programme, and Fondation pour la Recherche Medicale.
- Subjects :
- Adult
Male
0301 basic medicine
congenital, hereditary, and neonatal diseases and abnormalities
medicine.medical_specialty
Population
Medizin
Cohort Studies
Young Adult
03 medical and health sciences
0302 clinical medicine
All institutes and research themes of the Radboud University Medical Center
Internal medicine
medicine
Spinocerebellar Ataxias
Humans
media_common.cataloged_instance
ddc:610
Longitudinal Studies
Age of Onset
European union
education
Survival rate
Aged
media_common
education.field_of_study
Proportional hazards model
business.industry
Hazard ratio
mortality [Spinocerebellar Ataxias]
Middle Aged
medicine.disease
Disorders of movement Donders Center for Medical Neuroscience [Radboudumc 3]
Europe
Survival Rate
030104 developmental biology
Disease Progression
Spinocerebellar ataxia
Female
Neurology (clinical)
Age of onset
business
030217 neurology & neurosurgery
Follow-Up Studies
Cohort study
Subjects
Details
- ISSN :
- 14744422
- Database :
- OpenAIRE
- Journal :
- Lancet Neurology, 17, 4, pp. 327-334, Lancet Neurology, 17, 327-334, The lancet <London> / Neurology 17(4), 327-334 (2018). doi:10.1016/S1474-4422(18)30042-5, ResearcherID
- Accession number :
- edsair.doi.dedup.....02bdab8eedcb1e50f5e4df77992d1659
- Full Text :
- https://doi.org/10.1016/S1474-4422(18)30042-5